New Insights into Immune Checkpoints’ Role in Controlling Inflammation

Immune checkpoints (ICs) have long been recognized as critical regulators of T-cell activity within the tumor microenvironment, acting as inhibitory receptors that dampen immune responses to allow tumors to evade destruction. This classical view has underpinned the success of immune checkpoint inhibitors (ICIs), therapies that unleash T cells to attack cancer more effectively. However, recent insights reveal that the functions of ICs extend well beyond local tumor immunity, reshaping our understanding of their broader roles in immune regulation.

Emerging evidence highlights that checkpoint pathways are intricately involved in maintaining systemic immune homeostasis. The occurrence of multisystem immune-related adverse events following ICI treatment suggests that these molecules influence immune balance throughout the body, not merely within tumors. Consequently, immune checkpoints are now seen as key integrators linking localized inflammatory microenvironments with systemic immune responses.

This paradigm shift is reinforced by observations of abnormal immune checkpoint activity in a spectrum of conditions, including infectious diseases, autoimmune disorders, metabolic and cardiovascular inflammation, and tissue injury. These findings underscore that ICs, such as PD-1/PD-L1, CTLA-4, TIGIT, TIM-3, and LAG-3, operate within complex inflammatory and metabolic networks, modulating immune exhaustion, tissue tolerance, and chronic inflammation beyond cancer contexts.

Crucially, a variety of inflammatory cues—including cytokines, metabolites, oxidative stress signals, and tissue-derived factors—can regulate checkpoint expression and function. The dynamic crosstalk between these signals shapes immune cell phenotypes and influences whether immune responses are amplified, subdued, or persist chronically. Thus, immune checkpoints serve as central hubs orchestrating the balance of immune activation and tolerance in diverse physiological and pathological settings.

By integrating checkpoint signaling with broader cytokine networks and metabolic reprogramming, researchers aim to develop precision immunotherapies that fine-tune immune modulation. Such strategies seek to maximize therapeutic efficacy against tumors while minimizing adverse events related to systemic immune dysregulation. This holistic approach represents a promising advance toward personalized medicine in immunotherapy.

The authors of the recent review published in TransMed call for an expanded conceptual framework that recognizes immune checkpoints as pivotal moderators in both local and systemic immune regulation. Understanding the molecular underpinnings of checkpoint pathways and their interactions with inflammatory signals may unlock novel avenues for treating not only cancer but also a wide array of inflammatory and autoimmune diseases.

This evolving perspective propels the field beyond the traditional tumor-centric model, inviting innovative research into how checkpoint modulation can balance immune protection with tissue homeostasis. As immune checkpoint biology continues to unfold, it holds the potential to transform therapeutic approaches across multiple disciplines, heralding new horizons in immunity and inflammation regulation.

Contact with the corresponding author Wangzhiqi Zhang emphasizes the importance of linking checkpoint biology to immune safety, aiming to harness these pathways thoughtfully in clinical applications. This insight may guide the future design of checkpoint-targeted therapies with improved precision and reduced systemic toxicity.